BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating their positions in mRNA-based cancer immunotherapies and vaccines. This strategic move aims to integrate CureVac’s platform with BioNTech’s pipeline to accelerate oncology and infectious disease product development.